newsfilter
← Latest News
PR Newswire·

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Phase 3 data on investigational bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa to be presented as a late-breaking platform presentationBRUSSELS and ATLANTA, March 16, 2023